The stock is down, but it isn't out yet.

Novo Nordisk A/S is seeking discounts from suppliers to lower its own costs as it grapples with rivals in the weight-loss ...

Novo Nordisk (NVO) is said to have written to suppliers seeking discounts to lower its cost base as the Danish drugmaker tries to regain leadership in the weight-loss drug market currently dominated ...

Agios stock skyrocketed to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully ...

Novo Nordisk stock has given investors a mixed ride over the past few years, with a 36.1% gain over 5 years but weaker recent ...

Hackers claim they stole 1.3TB of Novo Nordisk data, including clinical trial and AI model information, after issuing a $25 million demand.

Despite pandemic headwinds at launch, Novo Nordisk’s oral semaglutide med Rybelsus has come into its own. For all of 2022, Rybelsus sales more than doubled to 11.29 million Danish kroner (about $1.7 ...

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

Novo Nordisk A/S outlook: 2026 guidance warns revenue/profit declines as GLP-1 competition, pricing pressure & patent risks ...